GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support ...

GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...

NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.

GSK PLC closed 11.51% short of its 52-week high of £16.79, which the company achieved on September 9th.

This FTSE 100 pharmaceutical giant has been hit by fears of US tariffs and litigation over a key product, but this could mean ...

Big Pharma executives have not been shy about their desire for deals, but companies have been battling macro headwinds ...

An asthma drug biotech that was acquired in a deal with GSK plc worth up to $1.4 billion is now at the center of a lawsuit, ...

Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage -- ...

Sage Therapeutics Inc. has found itself a buyer that bested the unsolicited acquisition offer a few months ago from fellow ...

The US Food and Drug Administration (FDA) announced a forthcoming public advisory committee meeting (AdCom) of the Oncologic Drugs Advisory Committee to review GSK’s marketing application for Blenrep ...

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...